New evidence in the treatment of overactive bladder

Abstract

The treatment of OAB is often complex, and can require trials of multiple different treatment modalities. Although the treatment advances discussed in this review have augmented treatment of OAB, the condition continues to negatively impact quality of life for our ageing female population. Clinical trials and development of novel therapies continue to be paramount.

Long‐term safety and efficacy of the novel β3‐adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: A phase III prospective study

“…Anticholinergics have been the first‐line treatment for OAB over the past decades . However, many patients discontinue long‐term anticholinergic therapy because of limited efficacy and undesired class‐related AEs . Much attention has been directed toward β 3 ‐AR agonists as a new and alternative target of OAB, as the human bladder expresses a high level of β 3 ‐AR mRNA and β 3 ‐AR agonist relaxed detrusor smooth muscle .…”

The Effectiveness of Anticholinergic Therapy for Overactive Bladders: Systematic Review and Meta-Analysis

“…[6][7][8] Although anticholinergic medications have been shown to improve patients' symptoms, they create a widespread blockade of cholinergic activity that often results in side effects such as dry mouth, cognitive changes, constipation, urinary retention, blurred vision, and dyspepsia. 9 These problems can be difficult to manage, and may contribute to poor patient adherence to treatment. 10 The objective of this systematic review and meta-analysis was to examine the currently available evidence from randomized clinical trials (RCTs) about the outcomes of the pharmacological management of OAB, and to summarize the comparative effectiveness of the drugs available in Brazil.…”